Posted by Michael Wonder on 20 Feb 2019
Gilead receives approval in Canada for Yescarta (axicabtagene ciloleucel) CAR T therapy for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
19 February 2019 - Yescarta is a chimeric antigen receptor T-cell therapy that is custom-made for each patient from his or her own T cells.
Gilead Sciences Canada announced today that Health Canada has granted a Notice of Compliance (NOC) for Yescarta (axicabtagene ciloleucel), a new chimeric antigen receptor T (CAR T) cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL).
Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
